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ABSTRACT
Authorized generics are identical in formulation to brand drugs, manufactured by the brand
company but marketed as a generic. Generics, marketed by generic manufacturers, are required
to demonstrate pharmaceutical and bioequivalence to the brand drug, but repetition of clinical
trials is not required. This retrospective cohort study compared outcomes for generics and
authorized generics, which serves as a generic vs. brand proxy that minimizes bias against
generics. For the seven drugs studied between 1999-2014, 5,234 unique patients were on brand
drug prior to generic entry and 4,900 (93.6%) switched to a generic. During the 12-months
following the brand-to-generic switch, patients using generics vs. authorized generics were
similar in terms of outpatient visits, urgent care visits, hospitalizations, and medication
discontinuation. The likelihood of emergency department visits was slightly higher for
authorized generics compared with generics. These data suggest that generics were clinically no
worse than their proxy brand comparator.

2
This article is protected by copyright. All rights reserved.

INTRODUCTION
Generic drugs play an important role in controlling health care costs.(1, 2) Between 2003 and
2012, generic drug use realized savings of $1.2 trillion in health care expenditures.(3) In 2012
alone, health care savings of $217 billion was attributed to generic drug use.(3) Generic drugs
also have been associated with better adherence than brand drugs.(4, 5) While the economic and
adherence-related benefits of generic drug competition are clear, there is a perception among
some health care providers and patients that there is a lack of clinical therapeutic equivalence
between generic and brand drugs.(6, 7)

The U.S. Food and Drug Administration (FDA) has a rigorous approval process to ensure that a
generic drug is therapeutically equivalent to a reference product (usually the brand drug) prior to
releasing it into the market.(8) But for generic drugs, which are approved through an abbreviated
new drug application (ANDA), preclinical and clinical data to establish safety and efficacy are
not required. Rather, generic drugs must show bioequivalence to the approved brand by
demonstrating that the active ingredient has no significant difference in the rate and extent of
absorption at the site of drug action typically in healthy individuals.(9) While ANDAs help
expedite the generic drug approval process, bioequivalence studies are not designed to identify
clinical outcome differences or detect adverse events that may occur at different rates with
generic as opposed to brand drugs. Generic drugs are typically not required to contain the same
inactive ingredients as the branded product approved through the new drug application (NDA)
process, so it is possible that even though brand and generic products include the same active
ingredients, differences in safety or efficacy related to variability in the formulation may exist.
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Research to conclusively support or refute differences in clinical outcomes for brand vs. generic
products is limited.

A regulatory approach to address generic-brand equivalency concerns could be to modify the
approval process to require comparative clinical trials. But, equivalence studies with clinical
endpoints are less sensitive to formulation differences and would require considerably larger
sample sizes than are currently used in bioequivalence studies. Requiring prospective head-tohead clinical studies for the approval of generic drugs would increase costs associated with
bringing a generic drug to the market, and ultimately reduce competition and increase generic
prices. Thus, changing the regulatory approval requirements in this way is not a viable solution.
Post-marketing surveillance plays a valuable role in assessing lingering concerns regarding
possible differences in the efficacy or frequency of adverse events between generic and branded
drugs. However, patient and provider perceptions (i.e., public perception) that branded drugs are
superior to generics (10-17) are believed to introduce bias in post-market assessment of efficacy
and safety outcomes, making uncontrolled observational evaluation challenging.

One nuance in the generic drug market that provides an interesting research opportunity for
overcoming the public perception bias is the advent of authorized generics. Authorized generics
(AGs) are drugs that contain the same active and inactive ingredients as the branded product,
authorized and manufactured under the same NDA, with the only difference being that they are
labeled and marketed as generic drugs.(18) This compares to independent generics (i.e.,
“generics”), which are approved and marketed under an ANDA. Therefore, the safety and
efficacy profiles between an AG and the branded drug should be identical, while the safety and
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efficacy profile of generics could plausibly (although unlikely) differ from an AG or branded
drug. Since AGs and generics are similar in terms of their prescribing, dispensing, and cost to
patients (i.e., they are both perceived to be “generics”),(19) it is expected that both AGs and
generics and their cost are perceived equally. Therefore, comparing their utilization patterns and
outcomes provides a proxy for a brand vs. generic comparison that removes generic drug
perception bias.

To our knowledge, no previous studies have systematically compared branded products, AGs,
and generics to examine usage patterns and outcomes. The objectives of this study were to
compare brand-to-generic switching patterns and, among those switching to a generic, compare
outcomes for AG and generic drugs to determine if there is evidence in drug utilization patterns
and indicators of health services use that could be attributed to differences in therapeutic
equivalence between drug products. We hypothesized that the rates of health services use and
medication discontinuation would be similar for patients switching to an AG (i.e., brand drug
proxy) as opposed to a generic.

RESULTS
Across the seven drugs analyzed we identified 5,234 individual patients and 5,544 unique
person-drug combinations (Table 2) that were using an eligible brand drug and met other
inclusion criteria at the time of generic entry. For the full cohort, the mean age was
approximately 60 years and 71% were female (compared with 51.4% female overall in the SHP
population). Characteristics of the patients switching to generic were similar to characteristics of
the patients staying on brand, with the exception of defined daily dose, having an ED visit during
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the 6 months prior to generic entry, and the count of outpatient visits prior to generic entry.
Compared with the patients not switching to generic (i.e., non-switchers), the brand-to-generic
switchers tended to be on a higher mean daily dose (1.3 vs. 1.1 defined daily doses) and less
likely to have had an ED visit (14% vs. 20%) or an outpatient visit (mean of 6 vs. 7) during the 6
months prior to generic entry (p<0.05). A total of 3,762 switches were from brand to generic
(77%), while 1,138 switches were from brand to an AG (23%). The paroxetine and sertraline
sub-cohorts accounted for the highest proportion of AG switches (48% and 40%, respectively).

Switching from brand to generic was common among this cohort, with 94% switching to generic
during the first 12 months one was available. With the exception of gabapentin and simvastatin,
the majority (i.e., 80-95%) of brand to generic switching occurred within the first 3 months
following generic entry (Figure 1). For gabapentin and simvastatin, approximately 70% of
switching occurred within 3 months following generic entry. For gabapentin the percentage of
switchers continued to slowly increase through 12 months of follow-up, while for simvastatin
there was a sharp increase in brand-to-generic switching after 6 months of generic availability.
In the multivariable model of time to generic switching among the full cohort, the specific drug
was the most consistent predictor (Table 3). For example, brand-to-generic switching was faster
for alendronate (HR=1.25; 95% CI 1.15-1.36), amlodipine (HR=1.43; 95% CI 1.33-1.53), and
sertraline (HR=1.17; 95% CI 1.07-1.27), but slower for citalopram (HR=0.78; 95% CI0.72-0.84),
gabapentin (HR=0.67; 95% CI 0.58-0.77), paroxetine (HR=0.91; 95% CI0.83-0.99), and
simvastatin (HR=0.71; 95% CI0.64-0.78). Patient-related factors associated with a more rapid
brand-to-generic switch included having a higher defined daily dose (HR=1.09; 95% CI 1.05-
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1.13) and occurrence of a hospitalization during the 6 months prior to generic availability
(HR=1.15; 95% CI 1.02-1.29).

The patients who did not switch from brand to a generic were different from the switchers in
terms of their mean observation time following generic entry. The mean observation time was
78 days for non-switchers, 220 days for switchers to AG, and 276 days for switchers to generic.
On an annual basis the non-switchers had consistently higher rates of these outcomes than the
switchers. However, since our analysis was designed to determine whether the type of generic
drug (AG vs. generic) influenced outcomes we focused on the comparison of switchers to AG vs.
switchers to generic rather than comparing non-switchers to switchers (Table 4). We did not
observe differences between the AG and the generic switch groups in terms of the number of
outpatient visits, the number of urgent care visits, the number of ED visits, the occurrence or
number of hospitalizations, or the occurrence of medication discontinuation (P>0.05). However,
we did observe a difference in the occurrence of all-cause ED visits for the AG and generic
groups (P=0.006). In the switch to AG group, 27.6% (95% CI 24.5-30.8%) had an ED visit,
while only 22.8% (95% CI 21.3-24.3%) had an ED visit in the switch to generic group.

The difference in utilization outcomes between switchers to AG and switchers to generic was
statistically assessed via rate ratios for the negative binomial models and odds ratios for the
logistic models, adjusting for drug and other covariates (Figure 2). The adjusted comparison of
health services utilization and medication discontinuation illustrates no statistically significant
differences between the AG group and the generic group for outpatient visits, urgent care visits,
all-cause hospitalization, and medication discontinuation. The differences in all-cause ED use
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comparing switchers to AG versus switchers to generic was marginally significant in the
adjusted analyses, with an odds ratio of 1.33 (95% CI 1.11-1.61) for any ED visit and a rate ratio
of 1.23 (95% CI 1.02-1.47) for the number of ED visits per year.

Considering the unexpected differences observed in ED visits between the AG and the generic
groups, we explored whether individual drugs or other covariates might be particularly
influential in this finding (see supplementary tables). Considering, for example, the adjusted
odds ratios for any ED visits with individual drugs, we observed statistically significant
differences for the AG group vs. the generic group only for two drugs; alendronate (OR=4.09;
95% CI2.18-13.16) and sertraline (OR=1.65; 95% CI 1.23-2.16) had a higher likelihood of ED
visits for the AG group compared to the generic group.

DISCUSSION
In this study we compared brand-to-generic switching patterns and, among those switching to a
generic, we compared AG and generic users with regard to subsequent measures of health
services use and medication discontinuation. We conceptualized AG users to represent patients
who were taking a drug identical in formulation to a brand drug, but who perceived they were
using a generic drug. Therefore, comparison between AG and generic users indirectly represents
a brand vs generic comparison after controlling for generic drug perception bias.(10-17) In our
AG and generic comparison, we observed similar rates of outpatient visits, urgent care visits,
hospitalizations, and medication discontinuation. While we observed a higher likelihood of
using the ED and a higher number of ED visits among AG users compared to generic users, this
finding still supports that generics did not have worse outcomes than the AGs.
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The finding of higher likelihood of ED visits for patients switching to AG compared with generic
is surprising and needs further scrutiny. For instance, it is possible that inactive ingredients used
by the generic companies have a better safety profile than those used by the brand. But, it is also
possible that even though we controlled for patient-related factors and pre-index health services
use, there could be uncontrolled factors influencing who is getting an AG vs. a generic. For
example, physicians and pharmacists may be more comfortable to prescribe and dispense
generics produced by North American or European generic drug producers, yet we could not
consistently measure and control for this factor. There also could be regional or health planrelated factors that influence which patients get an AG vs. a generic, and these differences might
also be reflected in differential likelihood of using the ED. Health plan selection might also be
correlated with pharmacy usage, and pharmacy supply may vary geographically or by type of
pharmacy. When the AG and generic enter the market at the same time, pharmacies most likely
will stock either the AG or the generic, and the decision of which product to stock could be
influenced by wholesale distributors or buying groups. A plausible scenario to reflect AG vs.
generic selection bias could be that hospital outpatient pharmacies might receive better pricing
on AGs than community pharmacies, and therefore patients using the hospital outpatient
pharmacy would be more likely to receive AGs compared with patients using a community
pharmacy. Consequently, due to proximity of the hospital outpatient pharmacy with the ED, the
likelihood to receive the AG may be related to the access to the ED or the likelihood to seek care
at the ED. Future studies are needed to further explore potential unobserved confounding.
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Our analyses pooled data for seven drugs, which gave us the opportunity to study a large
population of users of various commonly used drugs with AGs in the market. However, the
group of drugs we studied influenced the cohort characteristics. For example, our cohort was
comprised of 71% females, compared with 51.4% females in the overall SHP population. This
appeared to be consistent with previously documented higher rates of female prescribing of
alendronate for osteoporosis (20) and antidepressants (e.g., citalopram, paroxetine, and
sertraline) for conditions such as depression or anxiety.(21) Possible differences between a
brand and generic also could be isolated to specific products rather than generalized across all
drugs. To address this concern we replicated our analyses for each individual drug. Although
the results are too lengthy for presentation here (see supplementary data), these analyses were
generally consistent with the pooled analyses with the exception of the ED visit outcome. The
individual drug analyses illustrated that the higher likelihood of an ED visit and the higher
number of ED visits for AG vs. generic was driven by alendronate and amlodipine, while
simvastatin illustrated an opposite relationship whereby ED visits were less common for those on
the AG vs. the generic. This emphasizes the importance of cautious interpretation of the pooled
data, and suggests that future evaluations should consider products individually. Moreover,
future research should consider that the group of generic drugs also may be heterogeneous and
assess individual generic drugs and formulations. This has been illustrated with historical
examples such as bupropion and methylphenidate, whereby post-marketing data led to a delayed
determination that specific generic formulations were not equivalent to the branded reference
drug.(22-24)
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Another complexity in making comparisons across different drugs relates to the timing of
generic drug availability. In many cases, the AG enters the market at the same time as the first
generic. In our analyses, amlodipine, citalopram, gabapentin, sertraline, and simvastatin had the
AG enter the market at the same time as the first generic. For alendronate and paroxetine,
however, the AG entered the market 6 months prior to the first generic (Table 1). In both of
these drugs, the 6-month delay in entry of the generic could have influenced switching patterns
and could have introduced additional confounding in our analyses.

We observed a rapid rate of switching from brand to generic among the insured population we
studied. This is likely a sign of effective formulary management by the health plan. We also
observed that the patients who did not switch from brand to generic were quite different from the
generic switchers in that they had shorter eligible follow-up time, lower defined daily dose,
higher percentage of pre-index ED visits, and a higher count of pre-index outpatient visits.
While we could have controlled for these factors when trying to compare outcomes of the
generic switchers and non-switchers, the small sample size and high health services utilization in
the non-switcher group did not allow for a meaningful comparison with the switcher groups.
Future research might consider using patients with stable brand drug use prior to generic
availability as their own controls for assessing outcomes after switching to a generic drug.

We believe our analysis had several key strengths that should be considered in light of the
challenges and limitations previously described. First, we believe that use of the AG as a brand
drug proxy is a novel way to study generic drug equivalence in the post-marketing environment.
While this research method may not be confirmatory in assessing problems with brand and
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generic clinical equivalence, we believe it could be a valuable surveillance tool to trigger further
investigation when differences between AG and generic drugs are identified. Second, it should
not be overlooked that the majority of outcome measures we evaluated suggested that patients
using AG drugs had similar outcomes as patients using generic drugs. This is a reassuring
indicator that generic drugs are generally tolerable (i.e., indirectly measured by medication
discontinuation rates) and have similar risk of need for higher levels of care (i.e., all-cause
hospitalization) as their corresponding AG drugs that are chemically identical to the branded
reference drug. Finally, by linking insurance claims data with electronic medical record data we
were able to robustly capture medication and health services use. We believe this allowed for a
more comprehensive measurement than using either of these data sources on their own.(25)

In conclusion, this study found similar likelihood of hospitalization and medication
discontinuation between AG and generic drugs, which indirectly supports similar outcomes for
generic compared with brand drugs. The finding of higher ED visits with AG compared with
generic drugs needs further investigation.

METHODS
Study Design
We conducted a series of retrospective cohort studies among patients receiving select branded
drugs prior to generic drug entry. Included drugs were selected based on evidence that both an
AG and generic were marketed at an overlapping point between the years 1999 and 2014 (Table
1). These drugs included alendronate, amlodipine, citalopram, gabapentin, paroxetine, sertraline,
and simvastatin. The sample of drugs was not based on similarities in pharmacological action or
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therapeutic uses, but rather we considered drugs with a sufficient sample size of users in our data
set at the time of generic entry (i.e., the date of first U.S. marketing of an AG or generic). The
date of the first generic prescription claim in our data was considered the index date for each
drug, and this date marked the beginning of follow-up to evaluate brand-to-generic switching
patterns over the subsequent 30 months. For patients who switched to a generic, the date of each
individual’s first generic prescription claim marked the index date for evaluating subsequent
outcomes with that product. For comparison with patients that did not switch to generic, we
marked the beginning of the follow-up period by using a randomly selected imputed
counterfactual switch date. Health services utilization and medication discontinuation were
measured for up to 12 months following the brand-to-generic switch or the counterfactual date
(for non-switching patients). The study was approved by the Institutional Review Boards of the
Marshfield Clinic Research Foundation and Auburn University, and by the U.S. FDA Research
Involving Human Subjects Committee (RIHSC).

Data
Administrative claims data from a regional insurance provider (Security Health Plan (SHP))
were combined with electronic health record (EHR) data from the Marshfield Clinic (MC),
which is an integrated health care delivery system that provides the majority of healthcare
services to 1.5 million patients residing in more than 50 locations in northern, central, and
western Wisconsin. The MC has coded diagnoses dating back to the early 1960s, and a fully
modern integrated EHR and data warehouse beginning in the 1990s. On average 102,700 SHP
insured beneficiaries have full year insurance coverage, with claims data including inpatient,
outpatient, and pharmacy claims. Approximately 65% of the SHP population having full year
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insurance coverage have evidence of use of MC clinics and their providers as reflected by at least
one recorded diagnosis in their EHR record. Drug use was measured and classified based on the
SHP claims data that include the National Drug Code (NDC) for the dispensed drug, and health
services utilization and related covariates were measured using both the SHP claims data and the
MC EHR data.

Study Sample
Data from 1999 through 2014 were used to apply the following inclusion criteria: 1) continuous
enrollment in SHP in the 6 months prior to generic introduction, with continuous enrollment
defined as no gaps in enrollment greater than 31 days; 2) continuous enrollment through at least
the first eligible prescription fill following generic availability; 3) at least 1 encounter per year in
the MC system; 4) at least 1 brand prescription of interest during the 6 months pre-generic
availability; and 5) at least 1 prescription fill of a medication in the therapeutic area within 12
months following generic availability.

Main Outcome Measures
Generic switch was defined as a patient switching from the branded drug to an AG or generic
during the 30-month period after each drug’s index date. We assumed that the dispensing date of
the AG or generic reflected the date the patient began taking the respective generic drug.
Patients who stayed on the branded drugs until the end of observation were defined as nonswitchers. Treatment discontinuation was defined as a gap in medication supply exceeding 90
days during the 12-month period after the initial generic switch (or following the counterfactual
switch date for the non-switchers).(26, 27) For both brand-to-generic switchers and non-
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switchers, patients discontinuing treatment were censored at the time of discontinuation in
analyses of health services use. This measure of treatment discontinuation was used as a proxy
to measure possible differences in efficacy or tolerability between switchers to an AG and
generic drug.

Health services utilization was quantified during the 12-month period after the initial generic
switch or counterfactual switch date using both the EHR data and SHP claims. Health services
utilization measures included all-cause hospitalization and emergency department (ED) visits,
number of urgent care visits, and number of outpatient visits. All-cause hospitalizations and ED
visits were measured as both binary and count variables.

Covariates
Covariates were measured during the 6-month pre-index period. These included demographics
(age and sex), the proportion of other prescriptions the patient received that were filled with a
brand drug, defined daily dosage of the last prescription prior to generic switch,(28) Charlson
comorbidity index,(29) any pre-index all-cause hospitalizations, any pre-index all-cause ED
visits, and the number of pre-index outpatient visits.

Statistical Analysis
Descriptive statistics were used to summarize characteristics of the switchers and non-switchers,
stratifying the switchers by whether they switched to an AG or generic. Independent sample ttests and Chi-square tests were used to compare continuous and categorical characteristics,
respectively, between the switcher and non-switcher group. Time to generic switching was
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evaluated using the Kaplan–Meier method, a conditional probability approach that we used to
measure the fraction of patients that did not switch from brand-to-generic over the 12-month
time period following generic entry. Multivariable Cox proportional hazards models were used
to evaluate factors associated with the time to generic switch, reporting the median estimated
hazard ratio (HR) and 95% confidence interval (CI) across 1000 bootstrapped samples. Drugs
were first considered as individual cohorts, and then combined as an aggregated cohort with time
anchored to the index date of generic entry for each drug. Combined analyses controlled for
individual drug effects. Unless otherwise specified, results are shown for the combined
population.

Among the sample of brand-to-generic switchers, the AG and generic groups were compared
using multivariable models to assess health services utilization and medication discontinuation
outcomes. Because of differences in observation time between groups, we estimated the
occurrence and number of outpatient, urgent care, emergency department, and hospital visits on
an annual basis using univariate negative binomial regression for count variables and logistic
regression for binary variables. For binary outcome variables (hospitalization, ED events, and
medication discontinuation), generalized logistic regression was used to fit a cumulative logit
model reporting the median odds ratio (OR) and 95% CI across 20 bootstrapped samples.
Negative binomial regression was used to model count variables (number of outpatient or urgent
care visits), reporting the median rate ratio (RR) and 95% CI across 20 bootstrapped samples.
Because of small sample sizes in some drug-specific switch groups, the number of covariates in
these models was reduced to include only age, defined daily dose, and Charlson score since these
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were the most influential variables in bivariable analyses. All analyses were performed using
SAS 9.3 (SAS Institute, Inc., Cary, NC) and the statistical significance was set at P<0.05.

STUDY HIGHLIGHTS
What is the current knowledge on the topic? Generic drugs save healthcare dollars, but some
patients and providers question whether outcomes are the same as brands. Post-marketing
comparisons of brand and generic outcomes are limited by generic drug perception biases.
These biases can be addressed by studying AGs, which are chemically identical to brand drugs
but still perceived as generics.
What question did this study address? Are there differences in outcome measures between AGs
(i.e., brand proxy) and generic drugs?
What this study adds to our knowledge: Patients using AGs were similar to patients on generics
in terms of outpatient visits, urgent care visits, hospitalizations, and medication discontinuation,
but the likelihood of emergency department visits was slightly higher for AGs compared with
generics.
How this might change clinical pharmacology or translational science: Post-marketing
surveillance can compare AGs vs. generics as a way to minimize bias in observational designs.
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FIGURE LEGENDS

Figure 1: Time from generic entry (index date) to generic switch by drug type

Figure 2: Adjusted comparison of health services utilization and medication
discontinuation for authorized generic vs. generic
AG = authorized generic; “Generic” refers to all other independing generics filed under an Abbreviated
New Drug Application (ANDA)
Estimates greater than 1 suggest that the outcome was more likely to occur in the AG group, while
estimates less than 1 suggest that the outcome was more likely to occur in the generic group.
Supplementary Materials

Supplementary Table: Drug and health services utilization among individual drug cohorts
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Outcome
Number of all-cause
outpatient visits per year

Lower Upper
Estimate
CI
CI P-Value
1.05

1

1.1

0.071

1.08

0.9

1.29

0.395

All-cause emergency department visits
Any visit
1.33

Number of all-cause urgent
care visits per year

1.11

1.61

0.003

Number per year

1.23

1.02

1.47

0.026

All-cause hospitalizations
Any visit
Number per year

1.14
1.09

0.91
0.81

1.43
1.46

0.257
0.582

Medication discontinuation

0.95

0.8

1.12

0.508

0.5

Favors Generic

1
Estimate
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Favors AG

2

Table 1: Products with authorized generics assessed in this study
Drug

Form/Strentghs

Therapeutic
Class

Date of First
Reference
Listed Drug
(Brand)

Date of First
Authorized
Generic (AG)

Date of First
ANDA-Approved
Generic
(Generic)

Number of FDA
ANDA
Approvals*

Alendronate

Tablets, 35 &
70MG
Tablets, 2.5,
5 & 10MG
Tablets, 10,
20 & 40MG
Capsules, 100, 300
& 400MG
Tablets, 10,
20, 30 & 40MG
Tablets, 25,
50 & 100MG
Tablets, 5, 10, 20,
40 & 80MG

Osteoporosis

9/29/95

2/6/08

8/4/08

13

Cardiovascular

7/31/92

3/23/07

3/23/07

34

Antidepressant

7/17/98

10/28/04

10/28/04

25

Antiepileptic

12/30/93

10/8/04

10/4/04

18

Antidepressant

12/29/92

3/5/03

9/8/03

12

Antidepressant

12/30/91

8/14/06

8/14/06

26

Cardiovascular

12/23/91

6/23/06

6/23/06

14

Amlodipine
Citalopram
Gabapentin
Paroxetine
Sertraline
Simvastatin

*Number of Abbreviated New Drug Applications (ANDAs) approved by the FDA for each drug as of December 31, 2014. A sponsor company may have multiple ANDAs fror the same drug.
AG = authorized generic; “Generic” refers to all other independing generics filed under an ANDA
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Table 2: Characteristics of brand to generic switchers and non-switchers (N=5234)
Switch Type *
Non-Switchers
334 (6%)

All
Switchers
4900 (94%)

Brand to
AG
1138 (23%)

Brand to
Generic
3762 (77%)

P-value:
switchers vs.
non-switchers
-

59 ± 17
94 (28%)
59%
1.1 ± 0.7
0.6 ± 1.1
39 (12%)
68 (20%)
7

60 ± 18
1421 (29%)
60%
1.3 ± 0.8
0.6 ± 1.1
485 (10%)
696 (14%)
6

56 ± 18
355 (31%)
62%
1.3 ± 0.8
0.6 ± 1.1
109 (10%)
190 (17%)
6

61 ± 17
1068 (28%)
59%
1.2 ± 0.7
0.6 ± 1.1
372 (10%)
508 (14%)
6

0.712
0.756
0.731
<0.001
0.615
0.298
0.003
0.007

57 (6%)
42 (3%)
69 (8%)
55 (20%)
39 (6%)
35 (5%)
52 (8%)

873 (94%)
1445 (97%)
744 (92%)
224 (80%)
630 (94%)
695 (95%)
584 (92%)

41 (5%)
289 (20%)
74 (10%)
25 (11%)
302 (48%)
278 (40%)
176 (30%)

832 (95%)
1156 (80%)
670 (90%)
199 (89%)
328 (52%)
417 (60%)
408 (70%)

-

Characteristic
Sample; n (%)
Demographics
Age; mean (SD)
Sex; n (%) male
Proportion of pre-index brand use; %
Pre-index defined daily dose (mean, SD)
Charlson comorbidity index (mean, SD)
Pre-index hospitalization; n (%)
Pre-index ED visit; n (%)
Pre-index outpatient visit count (median)
Switchers by Drug; n (%) **
Alendronate (n=930)
Amlodipine (n=1487)
Citalopram (n=813)
Gabapentin (n=279)
Paroxetine (n=669)
Sertraline (n=730)
Simvastatin (n=636)
*

The percentages of switchers by switch type are reflected as a percentage of all switchers
Some individuals qualified for multiple drug cohorts. In the full cohort the first person-drug combination was selected and subsequent observations for other drugs were excluded. This results in 5234
unique patients in the full cohort, but 5544 unique person-drug combinations.
AG = authorized generic; “Generic” refers to all other independing generics filed under an Abbreviated New Drug Application (ANDA); ED = emergency department

**

This article is protected by copyright. All rights reserved.

Table 3: Predictors of time to generic switching
Characteristic
(N=5234)*
Age (in years)
Male
Proportion of pre-index brand use; %
Pre-index defined daily dose
Charlson comorbidity index
Pre-index hospitalization
Pre-index ED visit
Pre-index outpatient visit count
Alendronate**
Amlodipine
Citalopram
Gabapentin
Paroxetine
Sertraline
Simvastatin

Hazard
Ratio
1.00
0.97
0.91
1.09
0.98
1.15
0.96
1.00
1.25
1.43
0.78
0.67
0.91
1.17
0.71

95% Confidence Interval
Lower
Upper
Limit
Limit
1.00
1.00
0.91
1.03
0.81
1.04
1.05
1.13
0.95
1.01
1.02
1.29
0.87
1.05
1.00
1.00
1.15
1.36
1.33
1.53
0.72
0.84
0.58
0.77
0.83
0.99
1.07
1.27
0.64
0.78

P-value
0.9313
0.3593
0.158
<0.0001
0.1833
0.0195
0.367
0.8124
<0.0001
<0.0001
<0.0001
<0.0001
0.031
0.0006
<0.0001

ED = emergency department
* Analyses include 5234 unique patients; for those (among the 5544) exposed to more than one of the seven drugs, the drug of first exposure is
the drug analyzed.
** In the absence of a specific comparison (control) drug, we present results for each drug contrasted with the combined cohort for the other six
drugs. Results for each drug come from separate models, each using a unique indicator (e.g., Alendronate=1, all other drugs=0).
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Table 4: Drug and health services utilization among non-switchers and switchers to authorized generic vs. generic
Switchers by Type
Utilization
Annual number of all-cause outpatient visits (mean, 95% CI)
Annual number of all-cause urgent care visits (mean, 95% CI)
Annual all-cause emergency department visits
Any visit (%, 95% CI)
Number per year (mean, 95% CI)
Annual all-cause hospitalizations
Any visit (%, 95% CI)
Number per year (mean, 95% CI)
Medication discontinuation (%, 95% CI)

NonSwitchers
20.8 (18.4-23.6)
11.4 (8.2-15.8)

Brand to AG
17.5 (16.6-18.5)
0.6 (0.5-0.7)

Brand to Generic
17.4 (16.9-17.9)
0.5 (0.5-0.6)

AG vs.
Generic
P-value
0.819
0.140

32.2 (23.8-41.9)
0.7 (0.4-1.0)

27.6 (24.5-30.8)
0.5 (0.4-0.6)

22.8 (21.3-24.3)
0.4 (0.4-0.5)

0.006
0.074

26.0 (18.1-35.8)
2.5 (1.4-4.6)
99.4 (99.2-99.6)

17.7 (15.1-20.6)
1.4 (1.0-1.8)
35.2 (32.0-38.5)

17.7 (16.4-19.1)
1.5 (1.3-1.7)
34.8 (33.2-36.5)

0.997
0.641
0.854

The mean observation time was 78 days for non-switchers, 220 days for switchers to AG, and 276 days for switchers to generic. Because of these differences in observation time the occurrence and
number of outpatient, urgent care, emergency department, and hospital visits was estimated on an annual basis using univariate negative binomial regression for count variables and logistic regression
for binary variables without adjusting for covariates. The difference in utilization between switchers to AG and switchers to generic was assessed via rate ratios for the negative binomial models and
odds ratios for the logistic models, with statistical significance reflected by P<0.05.
AG = authorized generic; “Generic” refers to all other independent generics filed under an Abbreviated New Drug Application (ANDA)
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